BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37265226)

  • 21. To Use or Not to Use 131I in Thyroid Cancer.
    Metter D; Phillips WT; Walker RC; Blumhardt R
    Clin Nucl Med; 2018 Sep; 43(9):670-671. PubMed ID: 30080184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing potential impact of 2015 American Thyroid Association guidelines on community standard practice for I-131 treatment of low-risk differentiated thyroid cancer: case study of Jordan.
    Juweid ME; Rabadi NJ; Tulchinsky M; Aloqaily M; Al-Momani A; Arabiat M; Abu Ain G; Al Hawari H; Al-Momani M; Mismar A; Abulaban A; Taha I; Alhouri A; Zayed A; Albsoul N; Al-Abbadi MA
    Endocrine; 2021 Sep; 73(3):633-640. PubMed ID: 33772746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcomes of a cohort of 271 patients with lung metastases from differentiated thyroid carcinoma.
    Maciel J; Cavaco D; Silvestre C; Simões Pereira J; Vilar H; Leite V
    Clin Endocrinol (Oxf); 2022 Dec; 97(6):814-821. PubMed ID: 35192239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiotheragnostics Paradigm for Radioactive Iodine (Iodide) Management of Differentiated Thyroid Cancer.
    Slonimsky E; Tulchinsky M
    Curr Pharm Des; 2020; 26(31):3812-3827. PubMed ID: 32503402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating the 2015 American Thyroid Association Risk Stratification System in High-Risk Papillary and Follicular Thyroid Cancer Patients.
    van Velsen EFS; Stegenga MT; van Kemenade FJ; Kam BLR; van Ginhoven TM; Visser WE; Peeters RP
    Thyroid; 2019 Aug; 29(8):1073-1079. PubMed ID: 31140385
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.
    Iizuka Y; Katagiri T; Ogura K; Mizowaki T
    Ann Nucl Med; 2019 Jul; 33(7):495-501. PubMed ID: 30955202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low iodine diet for one week is sufficient for adequate preparation of high dose radioactive iodine ablation therapy of differentiated thyroid cancer patients in iodine-rich areas.
    Lee M; Lee YK; Jeon TJ; Chang HS; Kim BW; Lee YS; Park CS; Ryu YH
    Thyroid; 2014 Aug; 24(8):1289-96. PubMed ID: 24731156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patient Age Is an Independent Risk Factor of Relapse of Differentiated Thyroid Carcinoma and Improves the Performance of the American Thyroid Association Stratification System.
    Trimboli P; Piccardo A; Signore A; Valabrega S; Barnabei A; Santolamazza G; Di Paolo A; Stati V; Chiefari A; Vottari S; Simmaco M; Ferrarazzo G; Ceriani L; Appetecchia M; Giovanella L
    Thyroid; 2020 May; 30(5):713-719. PubMed ID: 31973653
    [No Abstract]   [Full Text] [Related]  

  • 29. Treatment intensity and control rates in combining external-beam radiotherapy and radioactive iodine therapy for metastatic or recurrent differentiated thyroid cancer.
    Makita K; Hamamoto Y; Tsuruoka S; Takata N; Urashima Y; Miyagawa M; Mochizuki T
    Int J Clin Oncol; 2020 Apr; 25(4):691-697. PubMed ID: 31897803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Timing of Radioactive Iodine Administration Does Not Influence Outcomes in Patients with Differentiated Thyroid Carcinoma.
    Scheffel RS; Zanella AB; Dora JM; Maia AL
    Thyroid; 2016 Nov; 26(11):1623-1629. PubMed ID: 27549175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system.
    Tuttle RM; Tala H; Shah J; Leboeuf R; Ghossein R; Gonen M; Brokhin M; Omry G; Fagin JA; Shaha A
    Thyroid; 2010 Dec; 20(12):1341-9. PubMed ID: 21034228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distant Metastasis in Pediatric and Adolescent Differentiated Thyroid Cancer: Clinical Outcomes and Risk Factor Analyses.
    Sugino K; Nagahama M; Kitagawa W; Ohkuwa K; Uruno T; Matsuzu K; Suzuki A; Tomoda C; Hames KY; Akaishi J; Masaki C; Ito K
    J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32813019
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dynamic Risk Stratification for Predicting Long-term Outcomes in Pediatric Differentiated Thyroid Cancers.
    Majeed AK; Satapathy S; Ballal S; Bal C
    J Clin Endocrinol Metab; 2023 May; 108(6):e208-e215. PubMed ID: 36577747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Initial and Dynamic Risk Stratification of Pediatric Patients With Differentiated Thyroid Cancer.
    Sung TY; Jeon MJ; Lee YH; Lee YM; Kwon H; Yoon JH; Chung KW; Kim WG; Song DE; Hong SJ
    J Clin Endocrinol Metab; 2017 Mar; 102(3):793-800. PubMed ID: 27809646
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trends in Pediatric Thyroid Cancer Incidence, Treatment, and Clinical Course in Korea During 2004-2016: A Nationwide Population-Based Study.
    Lee YA; Yun HR; Lee J; Moon H; Shin CH; Kim SG; Park YJ
    Thyroid; 2021 Jun; 31(6):902-911. PubMed ID: 33107409
    [No Abstract]   [Full Text] [Related]  

  • 36. Outcomes of Thyrotropin Alfa Versus Levothyroxine Withdrawal-Aided Radioiodine Therapy for Distant Metastasis of Papillary Thyroid Cancer.
    Simões-Pereira J; Ferreira TC; Limbert E; Cavaco BM; Leite V
    Thyroid; 2021 Oct; 31(10):1514-1522. PubMed ID: 34155923
    [No Abstract]   [Full Text] [Related]  

  • 37. Avidity and Outcomes of Radioiodine Therapy for Distant Metastasis of Distinct Types of Differentiated Thyroid Cancer.
    Simões-Pereira J; Mourinho N; Ferreira TC; Limbert E; Cavaco BM; Leite V
    J Clin Endocrinol Metab; 2021 Sep; 106(10):e3911-e3922. PubMed ID: 34134139
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radioactive iodine ablation post differentiated thyroid cancer surgery: an analysis of use and impact of the American Thyroid Association guidelines.
    Sia Y; Dave RV; Nour D; Miller JA; Skandarajah AR; Tasevski R
    ANZ J Surg; 2019 Nov; 89(11):E502-E506. PubMed ID: 31674140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antithyroglobulin Antibody Variation During Follow-Up Has a Good Prognostic Value for Preoperative Antithyroglobulin Antibody-Positive Differentiated Thyroid Cancer Patients: A Retrospective Study in Southwest China.
    Liu Q; Yin M; Li G
    Front Endocrinol (Lausanne); 2021; 12():774275. PubMed ID: 34975751
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concordance in postsurgical radioactive iodine therapy recommendations between Watson for Oncology and clinical practice in patients with differentiated thyroid carcinoma.
    Kim M; Kim BH; Kim JM; Kim EH; Kim K; Pak K; Jeon YK; Kim SS; Park H; Kang T; Lee BJ; Kim IJ
    Cancer; 2019 Aug; 125(16):2803-2809. PubMed ID: 31216369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.